Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
XvguKVZhpAwD5Vdc
